Akouos

60 articles about Akouos

• Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

  1/23/2024

  Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history of profound hearing loss.

• Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

  12/1/2022

  Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS).

• Lilly and Akouos Announce Expiration of Akouos Tender Offer

  11/30/2022

  Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share.

• Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

  11/14/2022

  Akouos, Inc. today reports financial results for the third quarter ended September 30, 2022 and provides business highlights.

• Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

  10/18/2022

  Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.

• 

  Lilly Continues Foray into Gene Therapies with $487M Akouos Buyout

  10/18/2022

  Eli Lilly is acquiring precision medicine biotech Akouos for $487 million in cash in a deal focused on developing gene therapies for hearing loss.
• 

  FDA Review: Abiomed, Mallinckrodt, Aro and More

  9/16/2022

  The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.

• Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss

  9/13/2022

  Akouos, Inc. (NASDAQ: AKUS), today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2, first in human, pediatric clinical trial of AK-OTOF, a gene therapy intended for the treatment of patients with otoferlin gene (OTOF)-mediated hearing loss.

• Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting

  5/19/2022

  Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting.

• Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights

  5/12/2022

  Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the first quarter ended March 31, 2022 and provides business highlights.

• Akouos to Present at Bank of America 2022 Healthcare Conference

  5/4/2022

  Akouos, Inc. announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Bank of America 2022 Healthcare Conference on Tuesday, May 10 at 10:00 a.m. PDT in Las Vegas, Nevada.

• Akouos to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting

  5/3/2022

  Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

• Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

  3/29/2022

  Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the fourth quarter and full year ended December 31, 2021 and provides business highlights.

• Akouos to Participate in Upcoming March 2022 Virtual Investor Conferences

  3/24/2022

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer will participate in two upcoming virtual investor conferences in March.

• 

  BioSpace Movers & Shakers, March 11

  3/11/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers

• Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer

  3/10/2022

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer.

• Akouos to Present at Cowen 42nd Annual Heath Care Conference

  3/1/2022

  Akouos, Inc. announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a panel discussion titled Auditory and Ophthalmology at the Cowen 42nd Annual Health Care Conference on Monday, March 7 at 2:10 p.m. EST.

• Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions

  2/7/2022

  Akouos, Inc. presented nonclinical data at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting that support future development of gene therapies targeting inner ear conditions.

• Akouos to Participate in Upcoming February 2022 Virtual Investor Conferences

  1/31/2022

  Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that members of the management team will participate in two upcoming virtual investor conferences in February:

• Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting

  1/7/2022

  Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting, which is being held in San Jose, California from February 5 to 9, 2022.